1. Home
  2. ACCL vs GLTO Comparison

ACCL vs GLTO Comparison

Compare ACCL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACCL

Acco Group Holdings Limited Ordinary Shares

N/A

Current Price

$3.10

Market Cap

57.8M

ML Signal

N/A

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$20.89

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCL
GLTO
Founded
2009
2011
Country
Hong Kong
Denmark
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
54.5M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
ACCL
GLTO
Price
$3.10
$20.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
82.0K
92.0K
Earning Date
02-20-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
2.91
N/A
EPS
0.08
N/A
Revenue
$4,888,824.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.11
N/A
Revenue Growth
11.91
N/A
52 Week Low
$2.10
$2.01
52 Week High
$5.00
$38.33

Technical Indicators

Market Signals
Indicator
ACCL
GLTO
Relative Strength Index (RSI) N/A 44.10
Support Level N/A $21.56
Resistance Level N/A $38.33
Average True Range (ATR) 0.00 3.98
MACD 0.00 -1.46
Stochastic Oscillator 0.00 4.74

Price Performance

Historical Comparison
ACCL
GLTO

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: